10x Genomics, Inc. (TXG) |
| 33.5 1.34 (4.17%) 06-04 16:00 |
| Open: | 32.16 |
| High: | 35.645 |
| Low: | 32.16 |
| Volume: | 3,763,767 |
| Market Cap: | 4,253(M) |
| PE Ratio: | -197.06 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Healthcare Information Services |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 41.63 |
| Resistance 1: | 35.65 |
| Pivot price: | 26.08 |
| Support 1: | 25.87 |
| Support 2: | 19.82 |
| 52w High: | 35.645 |
| 52w Low: | 8.945 |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
| EPS | -0.170 |
| Book Value | 6.240 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.808 |
| Profit Margin (%) | -3.55 |
| Operating Margin (%) | -11.30 |
| Return on Assets (ttm) | -4.5 |
| Return on Equity (ttm) | -3.0 |
Wed, 27 May 2026
10x Genomics (NASDAQ: TXG) CEO sells 28,893 shares under 10b5-1 tax-related plan - Stock Titan
Wed, 27 May 2026
10x Genomics (TXG) officer sells 11,595 shares to cover RSU taxes - Stock Titan
Wed, 27 May 2026
TXG Stock Chart | 10X GENOMICS INC-CLASS A (NASDAQ:TXG) - ChartMill
Tue, 26 May 2026
TXG - Finviz
Wed, 13 May 2026
Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results - simplywall.st
Tue, 12 May 2026
Is It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge? - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |